Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation.
Project:
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-301
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1427
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-483
,
Agencia Estatal de Investigación SAF2017-84324-C2-1-R
,
Agencia Estatal de Investigación PID2019-110137RB-I00
,
Agencia Estatal de Investigación PID2019-107145RB-I00
,
Instituto de Salud Carlos III PI17-01487
,
Instituto de Salud Carlos III PIC18-00014
,
Instituto de Salud Carlos III ICI19-00039
,
Instituto de Salud Carlos III PI18-00256
,
Instituto de Salud Carlos III PI18-01227
,
Instituto de Salud Carlos III ICI20-00135
,
Instituto de Salud Carlos III RD16-0009
,
Instituto de Salud Carlos III RD16-0011-0006
,
Instituto de Salud Carlos III CB16-11-00403
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2019-PROD-00122
,
Instituto de Salud Carlos III CPII15-00003
,
Instituto de Salud Carlos III PI16-00981